These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28705099)

  • 1. Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies.
    van den Tempel N; Odijk H; van Holthe N; Naipal K; Raams A; Eppink B; van Gent DC; Hardillo J; Verduijn GM; Drooger JC; van Rhoon GC; Smedts DHPM; van Doorn HC; Boormans JL; Jager A; Franckena M; Kanaar R
    Int J Hyperthermia; 2018 Jun; 34(4):407-414. PubMed ID: 28705099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination.
    van den Tempel N; Laffeber C; Odijk H; van Cappellen WA; van Rhoon GC; Franckena M; Kanaar R
    Oncotarget; 2017 Jul; 8(27):44593-44604. PubMed ID: 28574821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.
    Krawczyk PM; Eppink B; Essers J; Stap J; Rodermond H; Odijk H; Zelensky A; van Bree C; Stalpers LJ; Buist MR; Soullié T; Rens J; Verhagen HJ; O'Connor MJ; Franken NA; Ten Hagen TL; Kanaar R; Aten JA
    Proc Natl Acad Sci U S A; 2011 Jun; 108(24):9851-6. PubMed ID: 21555554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.
    Harnicek D; Kampmann E; Lauber K; Hennel R; Cardoso Martins AS; Guo Y; Belka C; Mörtl S; Gallmeier E; Kanaar R; Mansmann U; Hucl T; Lindner LH; Hiddemann W; Issels RD
    Int J Cancer; 2016 Jul; 139(2):467-79. PubMed ID: 26933761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    Kyle S; Thomas HD; Mitchell J; Curtin NJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    Oei AL; Ahire VR; van Leeuwen CM; Ten Cate R; Stalpers LJA; Crezee J; Kok HP; Franken NAP
    Int J Hyperthermia; 2018 Feb; 34(1):39-48. PubMed ID: 28540821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of chromosomal aberrations, induction of apoptosis, BRCA2 degradation and sensitization to radiation by hyperthermia.
    Bergs JW; Oei AL; Ten Cate R; Rodermond HM; Stalpers LJ; Barendsen GW; Franken NA
    Int J Mol Med; 2016 Jul; 38(1):243-50. PubMed ID: 27246457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies.
    Eppink B; Krawczyk PM; Stap J; Kanaar R
    Int J Hyperthermia; 2012; 28(6):509-17. PubMed ID: 22834701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
    del Rivero J; Kohn EC
    Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
    BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of PARP inhibitor sensitivity and resistance.
    D'Andrea AD
    DNA Repair (Amst); 2018 Nov; 71():172-176. PubMed ID: 30177437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
    Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW
    PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
    Oei AL; van Leeuwen CM; Ahire VR; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJA; Crezee J; Kok HP; Krawczyk PM; Kanaar R; Franken NAP
    Oncotarget; 2017 Apr; 8(17):28116-28124. PubMed ID: 28427225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.